1 |
Raina R, Mahajan Z, Sharma A, Chakraborty R, Mahajan S, Sethi SK, et al. Hypertensive crisis in pediatric patients: an overview. Front Pediatr 2020;8:58891.
|
2 |
Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G, et al. Stage III hypertension in patients after mRNA-based SARSCoV-2 vaccination. Hypertension 2021;77:e56-7.
|
3 |
Athyros VG, Doumas M. A possible case of hypertensive crisis with intracranial haemorrhage after an mRNA anti-COVID-19 vaccine. Angiology 2022;73:87.
|
4 |
Kim MS, Jung SY, Ahn JG, Park SJ, Shoenfeld Y, Kronbichler A, et al. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: a pharmacovigilance analysis using WHO international database. J Med Virol 2022;94:1085-95.
DOI
|
5 |
Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 vaccines: much accomplished, much to learn. Ann Intern Med 2021;174:687-90.
DOI
|
6 |
Pucci F, Annoni F, Dos Santos RA, Taccone FS, Rooman M. Quantifying renin-angiotensin-system alterations in COVID-19. Cells 2021;10:2755.
|
7 |
Mizuiri S, Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol 2015;4:74-82.
DOI
|
8 |
Schrier RW. Decade in review--polycystic kidney disease: slowing progression of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2015;11:638-9.
|
9 |
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol 2019;15:367-85.
|
10 |
Khani E, Entezari-Maleki T. Hypertensive crisis following COVID-19 vaccination. J Clin Pharmacol 2022;62:1047-8.
DOI
|